MilliporeSigma
All Photos(1)

Documents

SML3621

Sigma-Aldrich

Erlotinib

≥98% (HPLC)

Sign Into View Organizational & Contract Pricing

Synonym(s):
4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline, 6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]- (3-ethynyl-phenyl)amine, Erlotinib free base, N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, NSC 718781, OSI-774
Empirical Formula (Hill Notation):
C22H23N3O4
CAS Number:
Molecular Weight:
393.44
MDL number:

Quality Level

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
SML21561241619T4182
vibrant-m

SML3621

Erlotinib

vibrant-m

SML2156

Erlotinib hydrochloride

vibrant-m

1241619

Erlotinib Related Compound A

vibrant-m

T4182

Tyrphostin AG 1478

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

-

assay

≥98%

Quality Level

100

Quality Level

-

Quality Level

-

Quality Level

100

storage temp.

-10 to -25°C

storage temp.

−20°C

storage temp.

2-30°C

storage temp.

2-8°C

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear (warmed)

solubility

-

solubility

0.1 M HCl: soluble <0.4 mg/mL, DMSO:methanol (1:1): soluble 10 mg/mL, clear, colorless, ethanol: soluble 10 mg/mL, methylene chloride: soluble 10 mg/mL, 0.1 M NaOH: insoluble, 2-hydroxypropyl-β-cyclodextrin: insoluble, H2O: insoluble

color

white to beige

color

white to beige

color

-

color

-

Biochem/physiol Actions

Erlotinib is an orally available, potent, and specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Erlotinib binds to the ATP binding site of the receptor. It is used to treat lung and pancreatic cancer.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).

Example:

T1503
Product Number
-
25G
Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Jennifer Stamos et al.
The Journal of biological chemistry, 277(48), 46265-46272 (2002-08-28)
The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been determined to 2.6-A resolution, both with and without an EGFRK-specific inhibitor currently in Phase III clinical
Xiaoping He et al.
Scientific reports, 12(1), 8007-8007 (2022-05-15)
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Lenvatinib is approved as a first-line treatment for unresectable HCC. The therapeutic duration of lenvatinib is limited by resistance, but the underlying mechanism is unclear. To establish lenvatinib-resistant cells
Chike Osude et al.
Cells, 11(10) (2022-05-29)
NSCLC treatment includes targeting of EGFR with tyrosine kinase inhibitors (TKIs) such as Erlotinib; however, resistance to TKIs is commonly acquired through T790M EGFR mutations or overexpression of vascular endothelial growth factor receptor-2 (VEGFR-2). We investigated the mechanisms of EGFR-TKI

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service